Stock Events

Stock Events

Lipocine 

€3.94
0
-€0.00-0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
3.94
52W Low
3.94
Volume
-
Avg. Volume
0
Mkt Cap
32.52M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q1 2026
Q2 2026
Next
-0.46
-0.4
-0.34
-0.28
Expected EPS
-0.27545600000000003
Actual EPS
N/A

Financials

-493.09%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.69MRevenue
-8.33MNet Income

Analyst Ratings

0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2VT0.STU. It's not an investment recommendation.
Apple
8
AAPL
Plug Power
8
PLUG
Tesla
7
TSLA
AMD
7
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
ANI Pharmaceuticals
ANIP
Mkt Cap1.67B
ANI Pharmaceuticals competes in the specialty pharmaceutical market, focusing on developing and marketing treatments that could directly compete with Lipocine's hormone therapy products.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, having acquired Allergan, has a strong presence in the hormone therapy space, making it a direct competitor to Lipocine.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio of drugs, including hormone therapy products, that could compete with Lipocine's treatments.
Merck
MRK
Mkt Cap366B
Merck & Co. offers a variety of healthcare products, including hormone-related therapies, that could compete with Lipocine's product line.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries has a large generic and specialty medicine portfolio, including hormone therapies that could compete with Lipocine.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on innovative biologic treatments, some of which may compete in the same therapeutic areas as Lipocine's hormone therapy products.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb offers a wide range of prescription medications, including those in the hormone therapy space, potentially competing with Lipocine.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, produces a variety of medications, including hormone therapies that could compete with Lipocine's products.

About

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Show more...
CEO
Mahesh V. Patel
Employees
14
Country
United States
ISIN
US53630X2036
WKN
000A3EBZD

Listings

STU
DE
2VT0.STU
STU
DE
2VT.STU
XNAS
US
LPCN
BOATS
BOATS
LPCN.BOATS

0 Comments

Share your thoughts

FAQ

What is Lipocine stock price today?▼
The current price of 2VT0.STU is €3.94 EUR — it has decreased by -0% in the past 24 hours. Watch Lipocine stock price performance more closely on the chart.
What is Lipocine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Lipocine stocks are traded under the ticker 2VT0.STU.
Is Lipocine stock price growing?▼
2VT0.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Lipocine has showed a +0% increase.
What is Lipocine market cap?▼
Today Lipocine has the market capitalization of 32.52M
When is the next Lipocine earnings date?▼
Lipocine is going to release the next earnings report on November 11, 2026.
What were Lipocine earnings last quarter?▼
2VT0.STU earnings for the last quarter are -0.28 EUR per share, whereas the estimation was -0.35 EUR resulting in a +20% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Lipocine revenue for the last year?▼
Lipocine revenue for the last year amounts to 1.69M EUR.
What is Lipocine net income for the last year?▼
2VT0.STU net income for the last year is -8.33M EUR.
How many employees does Lipocine have?▼
As of September 06, 2026, the company has 14 employees.
In which sector is Lipocine located?▼
Lipocine operates in the Health & Wellness sector.
When did Lipocine complete a stock split?▼
The last stock split for Lipocine was on May 12, 2023 with a ratio of 1:17.
Where is Lipocine headquartered?▼
Lipocine is headquartered in SALT LAKE CITY, United States.